Skip to content
OpenCapital
Get started

ImmunityBio, Inc. IBRX Q4 2025 Annual earnings

Reported February 23, 2026 · Before market open

Revenue$38.3MMiss by $76.0K
EPS-$0.06Beat by $0.02
Revenue estimate$38.4M
EPS estimate-$0.08

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$49.7M
EPS estimate-$0.09

Financials

Q4 2025

Income statement

See full
Revenue$38.3M+407%
Gross profit$37.9M+402%
Operating income-$64.7M+6.8%
Net income-$61.9M-4.7%
EPS (diluted)-$0.06+33.3%

Balance sheet

See full
Cash & equivalents$88.3M-38.4%
Total debt$365.9M+12.0%
Total equity-$500.5M-2.3%
Total assets$501.9M+31.1%

Cash flow

See full
Operating cash flow-$70.4M+17.3%
CapEx$903.0K-57.2%
Free cash flow-$71.3M+18.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.95B+4.3%
Enterprise value$2.23B+8.5%
P/S17.2×-110×

Profitability

See full
Gross margin99.3%-0.7pp
Operating margin-226%-107pp
Net margin-310.2%-146pp
FCF margin-272.6%-129pp

Returns & leverage

See full
Current ratio5.1×+1.7×

Segments

By segment

See full
Reportable Segment$38.3M+407%

Versus estimates

Revenue

Q1 2026$44.2MBeat by $1.1M
Q4 2025$38.3MMiss by $76.0K
Q3 2025$32.1MMiss by $5.7MQ2 2025$26.4MMiss by $5.5MQ1 2025$16.5MMiss by $83.0KQ4 2024$7.6MMiss by $2.1M

Diluted EPS

Q1 2026-$0.09Miss by $0.01
Q4 2025-$0.06Beat by $0.02
Q3 2025-$0.07Beat by $0.03Q2 2025-$0.10In lineQ1 2025-$0.15Miss by $0.03Q4 2024-$0.15Beat by $0.11

Ask the moment ImmunityBio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ImmunityBio, Inc. report Q4 2025 earnings?
ImmunityBio, Inc. (IBRX) reported Q4 2025 earnings on February 23, 2026 before market open.
What were ImmunityBio, Inc.'s Q4 2025 revenue and EPS?
ImmunityBio, Inc. reported revenue of $38.3M and eps of $-0.06 for Q4 2025.
Did ImmunityBio, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $38.4M by $76.0K. EPS beat the consensus estimate of $-0.08 by $0.02.
How did ImmunityBio, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 407.0% from $7.6M a year earlier and eps grew 60.0% from $-0.15.
Where can I find ImmunityBio, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001326110-26-000025) and the 10-K periodic report (0001326110-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.